BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36351411)

  • 21. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas' disease.
    Leon JS; Wang K; Engman DM
    J Immunol; 2003 Oct; 171(8):4271-7. PubMed ID: 14530351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study.
    Zheng Y; Chen Z; Song W; Xu Y; Zhao Z; Sun Y; Wang Y; Geng X; Zhao J; Zhang X; Xu Y; Chan JSK; Tse G; Li G; Hong L; Liu T
    Cancer Med; 2024 May; 13(10):e7233. PubMed ID: 38752474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization.
    Wang X; Chen J; Shen Y; Zhang H; Xu Y; Zhang J; Cheng L
    Cytokine; 2024 Jul; 179():156620. PubMed ID: 38701735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice.
    Rubio-Infante N; Castillo EC; Alves-Figueiredo H; Ramos-González M; Salazar-Ramírez F; Salas-Treviño D; Soto-Domínguez A; Lozano O; García-Rivas G; Torre-Amione G
    ESC Heart Fail; 2024 Apr; 11(2):1249-1257. PubMed ID: 38049390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis.
    Lee JH; Kim TH; Park HE; Lee EG; Jung NC; Song JY; Seo HG; Seung KB; Chang K; Lim DS
    Cardiovasc Res; 2014 Feb; 101(2):203-10. PubMed ID: 24189626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
    Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
    Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
    J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
    Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
    Front Immunol; 2022; 13():804597. PubMed ID: 35432346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
    Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
    Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
    Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
    J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
    Tajiri K; Ieda M
    Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
    Lehmann LH; Cautela J; Palaskas N; Baik AH; Meijers WC; Allenbach Y; Alexandre J; Rassaf T; Müller OJ; Aras M; Asnani AH; Deswal A; Laufer-Perl M; Thuny F; Kerneis M; Hayek SS; Ederhy S; Salem JE; Moslehi JJ
    JAMA Cardiol; 2021 Nov; 6(11):1329-1337. PubMed ID: 34232253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
    Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
    Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R; Colin G; Calès V; Renault PA; Mazieres J
    Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
    Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
    J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral immune mapping and multi-omics analysis in Pd-1 inhibitor-induced myocarditis.
    Gao J; Wang Y; Lu L; Ma M; Ling J; Sun L; Chen Y; Liu F; Yu Y; Liu T; Wu D
    J Leukoc Biol; 2023 Jul; 114(2):164-179. PubMed ID: 37202883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.
    Champion SN; Stone JR
    Mod Pathol; 2020 Jan; 33(1):99-108. PubMed ID: 31534205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.